RxDoctor Payments Data

Kimberly Rauenzahn, DO

Family Medicine · Reading, PANPI 1235215567

Payments from drug & device makers

$15,885in general payments, 2019–2025

Across 998 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • Amgen$1K
  • Lilly USA, LLC$932
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$15,70699%
  • Education$1801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)144$2,413
Novo Nordisk91$1,892
AstraZeneca(2 entities)79$1,433
Pfizer106$1,189
Amgen(2 entities)66$1,084
Lilly USA, LLC52$932
Novartis35$653
Amarin Pharma, Inc.113$606
GSK25$445
Boehringer Ingelheim21$405
Sanofi-aventis U.S. LLC22$337
Teva Pharmaceuticals USA, Inc.16$285
Astellas Pharma US Inc15$281
Shield Therapeutics Inc8$254
Abbott11$219
Daiichi Sankyo Inc.8$193
Merck12$192
Lundbeck LLC9$190
Bayer10$189
Takeda Pharmaceuticals U.S.A., Inc.21$185
IBSA Pharma Inc.9$172
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$156
Amneal Pharmaceuticals LLC7$126
Johnson & Johnson7$108
Esperion Therapeutics, Inc.6$103
Eisai Inc.2$96
Kowa Pharmaceuticals America, Inc.7$96
Avanir Pharmaceuticals, Inc.6$90
Mylan Specialty L.p.3$75
Mannkind Corporation4$71
Sumitomo Pharma America, Inc.3$70
Mayne Pharma Commercial LLC5$69
Optos, Inc.2$67
Ironwood Pharmaceuticals, Inc4$58
Collegium Pharmaceutical, Inc.3$58
Biogen3$57
Paratek Pharmaceuticals, Inc.3$56
Currax Pharmaceuticals LLC4$55
Biofire Diagnostics, LLC1$54
Sanofi Pasteur Inc.3$48
Biohaven Pharmaceuticals, Inc.2$47
Scilex Pharmaceuticals Inc.2$47
Alnylam Pharmaceuticals Inc.2$44
Otsuka America Pharmaceutical, Inc.3$43
Axsome Therapeutics, Inc.2$42
VBI Vaccine (delaware) Inc.2$40
Kvk-tech, Inc.1$39
Idorsia Pharmaceuticals US Inc2$38
Inspire Medical Systems, Inc.1$36
Shire North American Group Inc2$32
Biohaven Pharmaceutical Holding Company Ltd.1$27
Sunovion Pharmaceuticals Inc.1$23
Philips North America LLC2$23
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$23
Supernus Pharmaceuticals, Inc.1$22
Viatris Specialty LLC1$20
Si-bone, Inc.1$20
Boston Scientific1$20
Clarus Therapeutics Inc.1$19
Nalpropion Pharmaceuticals LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,885 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$281,480
Medicare patients
590
Services billed
5,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$183,403
JardianceEmpagliflozin170$147,018
EliquisApixaban137$115,521
FarxigaDapagliflozin Propanediol147$112,750
MounjaroTirzepatide67$77,331
TrulicityDulaglutide59$70,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$63,142
JanuviaSitagliptin Phosphate70$54,488
ProliaDenosumab25$43,819
VascepaIcosapent Ethyl34$27,770
Janumet XrSitagliptin Phos/Metformin Hcl21$23,095
OxycontinOxycodone Hcl21$21,573
JanumetSitagliptin Phos/Metformin Hcl22$20,187
MyrbetriqMirabegron26$19,255
WegovySemaglutide15$19,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$1,892$202,655181 claims
Boehringer IngelheimJardiance, Tradjenta$405$153,051182 claims
Lilly USA, LLCMounjaro, Trulicity$932$147,554126 claims
PfizerEliquis$1,189$115,521137 claims
AstraZenecaFarxiga$1,433$112,750147 claims
MerckJanuvia, Janumet Xr, Janumet, Lagevrio (Eua)$192$108,114137 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Anoro Ellipta$445$82,996127 claims
AmgenProlia$1,084$43,81925 claims
Sanofi-aventis U.S. LLCMultaq, Soliqua 100-33$337$31,65929 claims
Johnson & JohnsonXarelto, Invokana$108$27,61540 claims
Astellas Pharma US IncMyrbetriq$281$19,25526 claims
AbbVieSynthroid$2,413$16,655220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →